1. Home
  2. MAMA vs BMEA Comparison

MAMA vs BMEA Comparison

Compare MAMA & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mama's Creations Inc.

MAMA

Mama's Creations Inc.

HOLD

Current Price

$13.53

Market Cap

474.8M

ML Signal

HOLD

Logo Biomea Fusion Inc.

BMEA

Biomea Fusion Inc.

HOLD

Current Price

$1.23

Market Cap

96.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MAMA
BMEA
Founded
2010
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Specialty Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
474.8M
96.9M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
MAMA
BMEA
Price
$13.53
$1.23
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
7
Target Price
$17.00
$8.71
AVG Volume (30 Days)
633.7K
1.5M
Earning Date
12-08-2025
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
41.91
N/A
EPS
0.12
N/A
Revenue
$151,312,000.00
N/A
Revenue This Year
$39.64
N/A
Revenue Next Year
$28.85
N/A
P/E Ratio
$114.25
N/A
Revenue Growth
29.92
N/A
52 Week Low
$5.50
$0.87
52 Week High
$14.97
$4.59

Technical Indicators

Market Signals
Indicator
MAMA
BMEA
Relative Strength Index (RSI) 61.94 45.23
Support Level $13.24 $1.30
Resistance Level $13.90 $1.34
Average True Range (ATR) 0.59 0.10
MACD -0.08 -0.01
Stochastic Oscillator 39.57 8.70

Price Performance

Historical Comparison
MAMA
BMEA

About MAMA Mama's Creations Inc.

Mama's Creations Inc is a marketer and manufacturer of fresh deli-prepared foods, found in grocery, mass, club, and convenience stores nationally. The company's broad product portfolio, born from a rich history in Italian foods, now consists of a variety of high-quality, fresh, clean, and easy-to-prepare foods to address the needs of both consumers and retailers. The brand of the company includes Mama's Creations, Mama's Mancini's, The Olive Branch, Creative Salads, and others.

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.

Share on Social Networks: